Patients with Crohn's disease treated with vedolizumab and corticosteroids had better remission rates than patients treated with corticosteroids alone, according to a study published in Inflammatory Bowel Diseases. Additional research is needed to see if the benefits continue after patients are switched to maintenance therapy, wrote Dr. Bruce Sands of the Icahn School of Medicine at Mount Sinai and colleagues.
Combination of vedolizumab, corticosteroids may improve Crohn's outcomes
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.